Area of research
Cardiology and Cardiovascular Medicine
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Cardiac pacing and defibrillation studies, and Cardiac electrophysiology and arrhythmias.
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <scp>EMPHASIS‐HF</scp> and <scp>RALES</scp>
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial
The Prevalence and Importance of Frailty in Heart Failure with Reduced Ejection Fraction – An Analysis of PARADIGM-HF and ATMOSPHERE
Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure
Cardiovascular Risk Associated with Serum Potassium in the Context of Mineralocorticoid Receptor Antagonist Use in Patients with Heart Failure and Left Ventricular Dysfunction
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Renal Function Stratified Dose Comparisons of Eplerenone Versus Placebo in the EMPHASIS-HF Trial
Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate
Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum
Declining Risk of Sudden Death in Heart Failure
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure
Effect of Eplerenone in Patients with Heart Failure and Reduced Ejection Fraction: Potential Effect Modification by Abdominal Obesity. Insight from the Emphasis-Hf Trial
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators
Contribution of Cardiac and Extra-Cardiac Disease Burden to Risk of Cardiovascular Outcomes Varies by Ejection Fraction in Heart Failure
Heart Rate and its Reduction in Chronic Heart Failure and Beyond
New Medicinal Products for Chronic Heart Failure: Advances in Clinical Trial Design and Efficacy Assessment
Efficacy of Sacubitril/Valsartan vs. Enalapril at Lower than Target Doses in Heart Failure with Reduced Ejection Fraction: The PARADIGM-HF Trial
Impact of Eplerenone on Cardiovascular Outcomes in Heart Failure Patients with Hypokalaemia
Challenges to Data Monitoring Committees When Regulatory Authorities Intervene
Aspirin does not Reduce the Clinical Benefits of the Mineralocorticoid Receptor Antagonist Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms: An Analysis of the EMPHASIS-HF Study
Length of Hospital Stay and 30-Day Readmission Following Heart Failure Hospitalization: Insights from the EVEREST Trial
Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial
Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial)
Clinical Outcomes According to QRS Duration and Morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)
Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial)
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure